Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

While reinforcing the importance of treating all known risk factors that contribute to atherosclerotic cardiovascular disease, ASCVD, physicians also need to recognize and treat systemic inflammation in CV disease, according to this guest column author who addresses the importance of identifying and reducing residual inflammatory risk.

Feature | Cardiac Diagnostics | By Robert L. Quigley, MD, DPhil

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes ...

January 23, 2024

Data from non-randomized cohort confirms dramatic improvement in diuretic response and at least 95% reduction in loop diuretic requirements up to almost four months after last DSR therapy

News | Heart Failure

Sequana Medical Announces DSMB Approval to Start Randomized MOJAVE Cohort

January 23, 2024 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

January 23, 2024

The International Stroke Conference 2024 will be held Feb. 7-9 in Phoenix, Arizona

News | AHA

International Stroke Conference 2024 to Present High-Profile Late-Breaking Science

January 23, 2024 — Focused on delivering the latest scientific advancements and new treatments in cerebrovascular ...

January 22, 2024

Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be more than 750,000 patients annually worldwide

News | Hypertension

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

January 19, 2024 — Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk ...

January 19, 2024

This study aims to compare the GORE VIABAHN VBX Balloon Expandable Endoprosthesis primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease with the goal of informing practice guidelines around which modality is best suited for patients with this condition

News | Stents

First Patients Enrolled in the Gore VBX Forward Clinical Study

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX FO ...

January 19, 2024

Abbott's Volt PFA System is designed to overcome limitations of first-generation PFA systems by providing physicians a clearer indication of contact between the Volt PFA Catheter and targeted tissue

News | Atrial Fibrillation

Abbott Announces First Global Procedures in a Clinical Trial of its Volt Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

January 18, 2024

Latest technology combines superior catheter design and sustained aspiration to maximize blood clot removal from the coronary vasculature

News | Thrombectomy Devices

Penumbra Launches Indigo System CAT RX Catheter in Europe to Address Acute Coronary Syndrome

January 16, 2024 — Penumbra, Inc., a thrombectomy company, has recently secured CE Mark (Conformité Européenne) for its ...

January 16, 2024

ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related hospitalization (CVH)), with a Win Ratio of 1.8 (p<0.0001)

News | Pharmaceuticals

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

January 12, 2024 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

January 12, 2024

The Journal of Lung and Heart Transplantation (JHLT) has published a real-world study indicating a significant reduction in Primary Graft Dysfunction (PGD), a severe post-transplant complication ― potentially allowing for an increase in donor hearts available for heart transplant patients

News | Cardiovascular Surgery

Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

January 11, 2024

New research from Mayo Clinic suggests that AI could improve the diagnosis of peripartum cardiomyopathy

News | Artificial Intelligence

Clinical Research Shows AI-enabled Digital Stethoscope can Detect Pregnancy-related Heart Disease

January 9, 2024 — New research from Mayo Clinic suggests that artificial intelligence (AI) could improve the diagnosis ...

January 09, 2024

Study investigators Drs. Pedro Engel-Gonzalez and Gennaro Giustino from Henry Ford Health.

News | Heart Valve Technology

Henry Ford Health Cardiologists Publish Case Series Study on Heart Valve Procedure

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

January 04, 2024

Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of enrollment in both their STIM-ADHF and STOP-ADHF pilot studies.

News | Cardiovascular Clinical Studies

Cardionomic Announces Enrollment Completion in the STIM-ADHF and STOP-ADHF Pilot Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

January 03, 2024

The first patient was enrolled at the Cleveland Clinic on December 28, 2023

News | Atrial Fibrillation

Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

December 29, 2023

Results from an ongoing clinical study conducted by Scripps Clinic indicate that MindMics' non-invasive IH technology can detect aortic stenosis by capturing in-ear acoustic vibrations throughout the cardiac cycles

News | Patient Monitors

MindMics Demonstrates Its In-ear Infrasonic Earbud Technology Shows Promise in Detection of Aortic Stenosis and Hearing Heart Murmurs

December 26, 2023 — MindMics, Inc. reported results from a clinical study of revolutionary earbuds that use a new ...

December 26, 2023

Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation

News | Atrial Fibrillation

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Catheter

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

December 26, 2023